VB50.F ALBERT LABS INTL. CORP.

Healthcare Biotechnology Frankfurt Exchange
0.0050 EUR
Close of Oct 10, 2026
0.0050 0.0050
Market cap
EUR 372K
P/E
-
P/B
17.00x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is VB50.F undervalued?

Graham number

The Graham number of ALBERT LABS INTL. CORP. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALBERT LABS INTL. CORP. fundamental analysis

No fundamental analysis for ALBERT LABS INTL. CORP. yet.

ALBERT LABS INTL. CORP. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALBERT LABS INTL. CORP.

Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.

Full company profile